<DOC>
	<DOCNO>NCT02931838</DOCNO>
	<brief_summary>A Study evaluate efficacy safety subject moderate severe Psoriasis treat BMS-986165</brief_summary>
	<brief_title>Study Evaluate Effectiveness Safety Subjects With Moderate Severe Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>For information regard BristolMyers Squibb Clinical Trial participation , please visit www.BMSStudyConnect.com Male female , age 18 70 year Diagnosis plaque psoriasis 6 month Women childbearing potential ( WOCBP ) must negative serum urine pregnancy test , must pregnant , lactate , breastfeed plan pregnancy Males sexually active WOCBP must agree follow instruction method ( ) contraception duration treatment plus 5 halflives study drug plus 90 day . Any significant acute chronic medical illness Blood transfusion within 4 week study drug administration Inability tolerate oral medication Positive hepatitisB ( HBV ) surface antigen Positive hepatitisC ( HCV ) antibody Any history risk tuberculosis ( TB ) Any major illness/condition evidence unstable clinical condition Chest Xray find suspicious infection screen receive ustekinumab , secukinumab ixekizumab within 6 month first administration study medication Has receive antiTumor Necrosis Factor ( TNF ) inhibitor ( ) within 2 month first administration study medication Has receive Rituximab within 6 month first administration study medication Topical medications/treatments psoriasis within 2 week first administration study medication Any systemic medications/treatments psoriasis within 4 week first administration study medication Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>